ArticleJournal of ovarian research2026
Exploring biomarkers of mitochondrial dynamics in polycystic ovary syndrome and the effect of mesenchymal stem cell transplantation on ovarian mitochondria.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a prevalent gynecological disorder commonly associated with endocrine, reproductive, and metabolic dysfunctions. Mitochondrial dynamics (MD) is essential for cellular homeostasis and is implicated in various metabolic disorders. However, its role in PCOS pathogenesis remains underexplored. Mesenchymal stem cells (MSCs) have shown significant promise in ovarian function restoration.
methodsEight differentially expressed mitochondrial dynamics-related genes (DE-MDRGs) were identified through analysis of PCOS transcriptomic data from public databases. Biomarkers for PCOS were validated based on expression levels. Gene set enrichment analysis (GSEA) was conducted to investigate the functional role of these biomarkers. The expression of these biomarkers was examined across distinct cell clusters in both PCOS and control groups. A PCOS rat model was created, MSCs were transplanted, and the relative expression of the biomarkers was confirmed via RT-qPCR.
resultsDDHD2 and MRAS were identified as potential biomarkers, both of which are co-enriched in immune response-related pathways. Granulosa cells (GCs) were categorized into four distinct clusters, with clusters GC2 and GC3 showing higher expression levels in PCOS, while GC1 was more prevalent in the controls. MRAS expression in GC1 was notably lower in PCOS compared to controls. RT-qPCR analysis further revealed that DDHD2 was down-regulated, while MRAS was up-regulated in PCOS. MSC transplantation ameliorated these imbalances.
conclusionDDHD2 and MRAS are promising novel biomarkers for PCOS, and MSCs appear to protect mitochondrial kinetic homeostasis, offering new insights and potential therapeutic avenues for clinical intervention in PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.